Skip to main content

Aditxt, Inc.

ADTX
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001726711

No open-market purchases or sales by Aditxt, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $0 in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Aditxt, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of ADTX: Q3 2022 compared with Q4 2022
MeasureQ3 2022Of which not filed for Q4 2022Q4 2022Change
Holders16116+1
Shares289.7K20697.5K+407.9K (+140.8%)
Value$983.2K$68$805.6K−$177.5K (−18.1%)

1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (3)

Institutions that held Aditxt, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to ADTX in Q4 2022
InstitutionSharesValue% of portfolio
Susquehanna International Group, LLP32,510$38.0K0.00%
StoneX Group Inc.12,405$14.3K0.00%
Natixis10,000$11.5K0.00%

Sold out (2)

Institutions that held Aditxt, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of ADTX in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Jane Street Group, LLC19,739$67.0K
Royal Bank of Canada1$0

Not filed for Q4 2022 yet (1)

Institutions that held Aditxt, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ADTX in Q3 2022 that haven't filed for Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
American Portfolios Advisors20$68